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Estimating trends in life expectancy in HIV-positive individuals 
Estimates of life expectancy are of obvious importance 
to people with HIV-1, and are essential to monitor 
and predict the progress of the HIV/AIDS epidemic 
and to plan health services. The Rwandan study 
reported by Sabin Nsanzimana and colleagues1 in 
The Lancet Global Health is the ﬁ rst from sub-Saharan 
Africa to focus on the evolution of HIV-positive life 
expectancy during the scale-up of antiretroviral therapy, 
and is a welcome addition to a small body of data. The 
investigators show that the scale-up of antiretroviral 
therapy resulted in substantial gains in life expectancy, 
with near-normal life expectancy in individuals enrolled 
in care with little immunodeﬁ ciency.1 
How reliable are estimates of life expectancy in people 
living with HIV? Life expectancy is the number of years 
that a person of a particular age would live, assuming 
that current age-speciﬁ c mortality rates remain 
constant. Calculations might thus seem straightforward, 
but for people living with HIV in sub-Saharan Africa 
they are not. First, analyses rely on data for patients 
in treatment and care programmes, which might not 
be representative of all individuals living with HIV-1.2 
Second, loss to follow-up of patients after the start 
of antiretroviral therapy is common.3 In the absence 
of functioning systems for vital statistics or outreach 
programmes to trace patients who were lost, mortality 
for these individuals remains unknown. To ignore the 
deaths in patients lost to follow-up substantially biases 
mortality downwards: death accounts for a substantial 
proportion of patients lost to follow-up.4 Last, the 
duration of follow-up needs to be standardised across 
calendar periods. The risk of death is not uniform 
after initiation of antiretroviral therapy, but falls with 
increasing duration of therapy.5 
Nsanzimana and colleagues1 addressed all of these 
issues. The researchers limited the duration of follow-
up to 3 years in all calendar periods, by contrast with 
other studies (eg, an analysis from the UK6 and a 
collaborative study in high-income countries7). The 
Rwandan study therefore controlled at least to some 
extent for survivor bias, although how similar lengths 
of follow-up were in the two calendar periods is unclear. 
Many patients from a nationally representative sample 
of clinics were included, which is an important strength 
of the study. Unfortunately, no information about 
mortality in patients lost to follow-up was obtained, but 
statistical adjustment was made assuming that about 
half of patients lost to follow-up had died. In Rwanda 
and many other countries in sub-Saharan Africa, vital 
statistics function poorly, with only a small number 
of deaths registered.8 The exception is South Africa, 
where coverage of vital registration is near universal 
and data from treatment and care programmes for HIV 
can be linked with mortality records to obtain accurate 
mortality estimates.9 The importance of the deaths 
among patients lost to follow-up in the Rwandan study 
is underlined by the much-higher estimates of life 
expectancy obtained when no adjustment was made, 
and uncertainty remains in this regard. 
How do the increases in life expectancy estimated 
for Rwanda compare with those of other studies, 
and how should they be interpreted? In Rwanda, the 
improvements were probably driven by changes over 
time in eligibility criteria for antiretroviral therapy and 
associated increases in CD4 counts at antiretroviral 
therapy initiation. Indeed, in a large-scale analysis of the 
International Epidemiologic Databases to Evaluate AIDS 
(IeDEA)10 that included patients starting antiretroviral 
therapy in 23 countries between 2002 and 2009, 
Rwanda had the highest annual increase in CD4 cell 
count at the start of therapy.11 However, whether any 
improvement in life expectancy would remain after 
Figure: Trends in life expectancy for individuals initiating antiretroviral 
therapy at age 35 years
Life expectancy estimates from Rwanda,1  South Africa,9 the UK,6 and 
high-income countries in North America and Europe7 are plotted at the 
midpoint of the calendar periods for which they are reported.
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controlling for these changes in baseline CD4 counts 
is unclear. Such an analysis addresses the question of 
whether or not the quality of HIV care has improved over 
time, which is important in view of the ever-increasing 
patient burden that treatment and care programmes for 
HIV face in sub-Saharan Africa.10 
Unfortunately, no trends in retention in care were 
presented by Nsanzimana and colleagues, and the 
method used to estimate life expectancy—the abridged 
life table method—is not well suited to answering 
questions about trends in quality of care, because it 
allows little scope for multivariate analysis. Using an 
alternative method—the relative survival model—we 
have recently shown that some improvement in life 
expectancy is likely to have occurred in South Africa, 
after controlling for both diﬀ erences in baseline CD4 
count and antiretroviral therapy duration across 
diﬀ erent calendar years.9 However, the improvement 
was small when compared with the more substantial 
improvements reported in studies from high-
income countries and the Rwandan study, which 
did not fully control for baseline CD4 count and 
duration of antiretroviral therapy (ﬁ gure). Finally, 
as the investigators point out,1 the improvements 
in life expectancy in Rwanda might partly be due to 
improvements in non-HIV mortality. 
The study by Nsanzimana and colleagues contributes 
to a growing evidence base on the successes and 
challenges of scaling up antiretroviral therapy in 
resource-limited settings. The reasons for the observed 
increases in life expectancy in people living with HIV 
in Rwanda are not entirely clear, however, and further 
research is needed to disentangle the eﬀ ects of loss to 
follow-up, changing  eligibility criteria for antiretroviral 
therapy, patient management systems, drug regimens, 
and non-HIV mortality.
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